Clinical Trial: TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria

U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07268131) titled 'TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria' on Nov. 24.

Brief Summary: This is a single-arm, single-center, prospective trial designed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with ipalimab/tuvonralimab (QL1706) in the peri-operative setting for resectable hepatocellular carcinoma exceeding the Milan criteria, and to explore biomarkers predictive of therapeutic response.

Study Start Date: Dec. 06

Study Type: INTERVENTIONAL

Condition: Hepatocellular Carcinoma (HCC)

Intervention: COMBINATION_PRODUCT: TACE+QL1706

T...